The business model followed by International Stem Cell Corporation, a California based biotechnology company with a powerful new stem cell technology called parthenogenesis that promises to significantly advance the field of regenerative medicine by addressing the problem of immune-rejection, is a novel one for the biotech industry. The model uses subsidiary business units to generate revenue from the sale of products developed from scientific discoveries made by ISCO. The model is self-sustaining since it provides the revenues to support the research and development used to generate the products. In addition, it provides practical applications of the core technologies, with valuable associated feedback.
Lifeline Cell Technology is a Maryland based wholly owned subsidiary of ISCO, specializing in the development and production of purified primary human cells and optimized reagents for cell culture. Lifeline’s scientists have been working in the field of cell culture for over 20 years, and have developed many of the human cell systems, as well as quality standards, used today in academic, government, and pharmaceutical laboratories to study human disease. The company is an industry leader, known for meticulous quality testing, innovation, and exceptional customer care.
Lifeline Skin Care is a California based wholly owned subsidiary of ISCO, specializing in the use of ISCO’s proprietary parthenogenetic stem cells for treatment of the skin. The company’s goal is to help individuals improve the look and feel of their skin by combining the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology, to create the highest quality, scientifically tested, and most effective skin care products.
ISCO protects its technology with worldwide patents. The company has approximately 90 pending patent applications across eight patent families, with 3 pending patents related to its skin care products.
In addition, the company has licensed a portfolio of 128 international patents or patent applications across 30 patent families, the majority being filed both in the U.S. and internationally, and covering most industrialized countries.
For additional information on ISCO, visit the company’s website at www.internationalstemcell.com
Let us hear your thoughts: International Stem Cell Corp. Message Board